
    
      The primary endpoint of the study is to determine the clinical efficacy as determined by the
      rate of morphological complete remission, of 2 different treatment regimens of temozolomide
      and vorinostat administered to 2 distinct groups of participants patients with AML and poor
      prognostic features. Participants will be allocated to treatment on the basis of
      O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status.
    
  